New specific VPS34 inhibitors (e.g. SAR-405) have been described in the past decade, but the development of some of them has been stopped after controversies around the effect of autophagy in cancer.104–106 However several companies are still developing VSP34 inhibitors for potential use in combination with targeted and immune therapies.107. Here, PIK3C3 is linked to cancer.